Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2004

01.06.2004 | Report

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

verfasst von: Beat Thürlimann, Dagmar Hess, Dieter Köberle, Isabella Senn, Pierluigi Ballabeni, Olivia Pagani, Lucien Perey, Stefan Aebi, Christoph Rochlitz, Aron Goldhirsch

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten
Metadaten
Titel
Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
verfasst von
Beat Thürlimann
Dagmar Hess
Dieter Köberle
Isabella Senn
Pierluigi Ballabeni
Olivia Pagani
Lucien Perey
Stefan Aebi
Christoph Rochlitz
Aron Goldhirsch
Publikationsdatum
01.06.2004
Verlag
Kluwer Academic Publishers
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2004
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000025420.78346.f9

Weitere Artikel der Ausgabe 3/2004

Breast Cancer Research and Treatment 3/2004 Zur Ausgabe

Instructions for Authors

Instructions for Authors

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.